Abstract
Imaging of sigma receptors in the living human brain is of interest because these receptors are potent targets for the treatment of neurological and neuropsychiatric diseases and brain ischemia. A number of radioligands have been developed for the imaging of sigma receptors, and a few, including [11C]SA4503, have been used in clinical studies for imaging in the human brain. The sigma1 receptor is distributed throughout the human brain. A widespread decrease in [11C]SA4503 binding in patients with Alzheimer's disease and a significant decrease in binding on the more affected side of the anterior putamen in patients with Parkinson's disease have been found. Drug-loading [11C]SA4503-positron emission tomography studies using therapeutic drugs for neurological and neuropsychiatric disorders have shown that some of the drugs had an affinity for sigma1 receptors in the human brain in addition to their main targets.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
